SCHEMBL23977089

SCHEMBL23977089

COC(=O)CCSc1cccc(Cl)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GAA P10253 2/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ GSTP1 P09211 1/20 0.40
▸ GSTM2 P28161 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CXCR1 P25024 1/20 0.39
▸ CXCR2 P25025 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ POLB P06746 3/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31381538 0.83 GSTP1 (0.40) MAPTALDH1A1MEN1KMT2AGSTP1
SCHEMBL22303520 0.83 MTNR1A (0.48) MAPTALDH1A1KMT2AGSTP1GSTM2
SCHEMBL23977091 0.82 KDM4E (0.41) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL19704645 0.77 GSTP1 (0.40) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL22303480 0.77 GSTP1 (0.40) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL20545177 0.74 PTGS2 (0.48) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL10588609 0.74 LMNA (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL2116085 0.74 CYP1A2 (0.54) MAPTALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL23406211 0.73 GSTP1 (0.37) MAPTALDH1A1SMN1; SMN2GSTP1GSTM2
SCHEMBL22493797 0.72 NOTUM (0.41) MAPTALDH1A1MEN1KMT2AGSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 — — US disclosed
CN-115485275-A Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof 诺华股份有限公司 2022-12-16 — — CN disclosed
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE HIF1AN, HIF1A, EGLN2 MAPT 4395/4885ALDH1A1 450/4885MEN1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback